Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial.

Elizabeth H. Phillips, S Devereux, J Radford, N Mir, T Adedayo, L Clifton-Hadley, R Johnson

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
JournalLeukemia & lymphoma
Publication statusPublished - 18 Feb 2019

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Cite this